Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA approves Sprycel for treatment of newly diagnosed Ph+ CML in chronic phase

Oct. 29, 2010

Astellas applies for Japanese marketing approval for degarelix for prostate cancer

Oct. 29, 2010

Combination of WX-671 and gemcitabine shows promise in phase II trial in pancreatic cancer

Oct. 29, 2010

Celator Pharma completes enrollment in phase II CPX-351 trial in AML

Oct. 28, 2010

Initial phase II results of resminostat in Hodgkin's lymphoma demonstrate favorable safety

Oct. 28, 2010

Treakisym approved in Japan for non-Hodgkin's and mantle cell lymphoma

Oct. 28, 2010

New clinical data presented on anticancer agents GSK-2118436 and GSK-1120212

Oct. 28, 2010

MolMed begins enrollment in phase II trial of NGR-hTNF in soft tissue sarcomas

Oct. 27, 2010

New inhibitors of dual specificity protein kinase TTK presented

Oct. 27, 2010

BMS-690514 shows potential to treat non-small cell lung cancer

Oct. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...